| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.09 | 0.1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |